Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
01 Apr 2019
Basal-bolus therapy using glargine 300 U/mL and insulin glulisine is superior to twice-daily injections of insulin degludec/aspart for glycaemic control without increasing the risk of hypoglycaemia, a new study suggests.

Improved antilipolytic effect in adipose tissue via SGLT2i attenuates weight loss in T2D patients

14 Aug 2019

Progressive lipolysis may be reduced via the improved antilipolytic effect in adipose tissue, which leads to a reduction in future weight loss caused by sodium-glucose cotransporter 2 inhibitors (SGLT2is) in patients with type 2 diabetes (T2D), suggests a recent study.

The authors analysed data from 774 patients with T2D (mean age, 58.5 years; glycosylated haemoglobin, 8.1 percent; body mass index, 25.6 kg/m2; estimated glomerular filtration rate, 83.9 mL/min/1.73m2; 66 percent men).

After decreasing significantly, weight loss plateaued between weeks 24 and 52. There was a significant decrease in fasting insulin levels from baseline to week 24, and this was maintained until week 52. Levels of fasting free fatty acids significantly increased and peaked at week 24 before decreasing at weeks 24–52.

Furthermore, levels of adipose tissue insulin resistance (Adipo-IR) decreased progressively all the way through week 52 (–3.6 and −6.2 mmol/L·pmol/L at weeks 24 and 52, respectively; p<0.001 for baseline vs weeks 24 and 52 and week 24 vs week 52). Higher baseline levels of Adipo-IR showed an independent association with greater weight loss at week 52.

This study sought to determine the mechanism of the attenuated weight loss during long-term treatment with an SGLT2i, tofogliflozin, focusing on the antilipolytic effect of insulin on adipose tissue. The authors conducted an integrated analysis using data from two phase III studies of 52 weeks of tofogliflozin administration.

Adipo-IR, calculated from the product of the levels of fasting insulin and fasting free fatty acids, was used to assess the antilipolytic effect.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
01 Apr 2019
Basal-bolus therapy using glargine 300 U/mL and insulin glulisine is superior to twice-daily injections of insulin degludec/aspart for glycaemic control without increasing the risk of hypoglycaemia, a new study suggests.